ADB-5'Br-BUTINACA

ADB-5'Br-BUTINACA (ADB-B-5Br-INACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist which has been sold as a designer drug,^[1] first detected in Philadelphia in the US in May 2022,^[2] and subsequently found in South Korea,^[3] Portugal and Sweden.^[4] It is specifically listed as an illegal drug in Italy,^[5] South Korea^[6] and several states in the US,^[7][8] and controlled under analogue legislation in various other jurisdictions.

ADB-5'Br-BUTINACA

Identifiers
IUPAC name N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-5-bromo-1-butylindazole-3-carboxamide
PubChem CID	168322646
ChemSpider	115005697
Chemical and physical data
Formula	C18H25BrN4O2
Molar mass	409.328 g·mol−1
3D model (JSmol)	Interactive image
SMILES NC(=O)[C@@H](NC(=O)c1nn(CCCC)c2ccc(Br)cc21)C(C)(C)C
InChI InChI=1S/C18H25BrN4O2/c1-5-6-9-23-13-8-7-11(19)10-12(13)14(22-23)17(25)21-15(16(20)24)18(2,3)4/h7-8,10,15H,5-6,9H2,1-4H3,(H2,20,24)(H,21,25)/t15-/m1/s1 Key:DIOILIVJIIJFPO-OAHLLOKOSA-N

See also

• ADB-BUTINACA
• ADB-5'Br-PINACA
• ADB-5'F-BUTINACA
• ADSB-FUB-187
• MDMB-5'Br-BUTINACA
• MDMB-BINACA